The U.S. Supreme Court has turned down an appeal attempt by Martin Shkreli this week.
The former CEO of Turing Pharmaceuticals rose to notoriety after raising the price of Daraprim, an anti-parasitic med used by HIV patients, by 5,000 percent in 2015. But ultimately Shkreli was sent to jail for defrauding investors. Shkreli was forced to pay $7.36 million and sentenced to seven years in a low-security prison in Pennsylvania.
Shkreli’s attorney called his appeal attempt to the Supreme Court a “long shot” and said his defense team was disappointed but will “move on.
Read the Reuters report.
